Intravitreal Ranibizumab Versus Bevacizumab for Treatment of Myopic Choroidal Neovascularization

Iacono, Pierluigi; Parodi, Maurizio Battaglia; Papayannis, Alessandro; Kontadakis, Stylianos; Sheth, Saumil; Cascavilla, Maria Lucia; Bandello, Francesco

doi:10.1097/iae.0b013e31826956b7

Cited by 73 publications

(75 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Discussionsupporting

confidence: 61%

“…In a recent prospective study with a follow-up of 18 months, Iacono et al [36] showed no difference between the two drugs regarding their ability to improve VA, confirming and expanding the preliminary results of Gharbiya et al [37]. However, ranibizumab displayed a greater effectiveness with respect to the mean number of injections required to achieve the same outcome [36]. In our study, the eyes were treated with both drugs; we cannot extrapolate the individual effect of each molecule, but our study suggests a clinical benefit from this class of drugs for the treatment of mCNV.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Anti-VEGF Therapy in Myopic Choroidal Neovascularization: Long-Term Results

Freitas-da-Costa

Pinheiro-Costa²,

Carvalho³

et al. 2014

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To evaluate the medium- and long-term efficacy of anti-VEGF agents in the treatment of choroidal neovascularization secondary to pathologic myopia (mCNV). Methods: We performed a retrospective analysis of patients with mCNV who had been treated with intravitreous anti-VEGF for at least 2 years. The best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were compared before and after the treatment. The number of injections per year was also assessed. Results: The results were analysed at 2 years for 67 eyes, at 3 years for 52 eyes, at 4 years for 28 eyes and at 5 years for 13 eyes. The mean change from baseline BCVA was significant at 2 years (+8.6 letters; p < 0.001) and this gain remained significantly stable for a period of 5 years. The mean CRT showed a significant decrease over time, with a nadir at 2 years (-104.0 μm; p < 0.001). The mean number of injections performed during the first year was 5.2, being lower in subsequent years (p < 0.001). Conclusion: In this subset of patients with mCNV, an intravitreous therapy with anti-VEGF agents proved to have effective results over 5 years, with a sustained increase in BCVA.

show abstract

Section: Discussionsupporting

confidence: 61%

Section: Discussionmentioning

confidence: 99%

Anti-VEGF Therapy in Myopic Choroidal Neovascularization: Long-Term Results

Freitas-da-Costa

Pinheiro-Costa²,

Carvalho³

et al. 2014

Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…Several studies have reported good visual results for MO in BRVO with bevacizumab intravitreal therapy at 6 months and 1 year [5,6]. Bevacizumab was also reported to be as effective as ranibizumab in other diverse macular diseases [7,8,9,10]. Consequently, the latter was widely used off-label in France in BRVO treatment before February 2011.…”

Section: Introductionmentioning

confidence: 99%

Prospective Pilot Study: Efficacy of Intravitreal Dexamethasone and Bevacizumab Injections in the Treatment of Macular Oedema Associated with Branch Retinal Vein Occlusion

et al. 2013

View full text Add to dashboard Cite

Background/Aims: To compare the efficacy of intravitreal injections of dexamethasone implants (IVD) with those of bevacizumab (IVB) for the treatment of macular oedema associated with branch retinal vein occlusion. Methods: A total of 19 patients (19 eyes) were included in this prospective pilot study. Initially, 8 eyes received three IVBs (group 1) and 11 received one IVD (group 2). All the patients underwent a 1-, 3-, 4- and 6-month follow-up visit. A repeated IVB (group 1) or IVD (group 2) was proposed at 4 months when necessary. Results: The mean visual acuity was significantly better 1 month after treatment in group 2, while the mean central macular thickness was also significantly lower in group 2. However, there was no longer any difference between the two groups at 3, 4 and 6 months, neither in terms of visual acuity nor in terms of retinal thickness. More than three IVBs were needed in 3 of 10 patients in group 1 while two IVDs were required in 10 of 11 patients in group 2. Conclusion: There was no significant difference between the two treatment regimens at the 6-month follow-up visit. A more rapid functional and anatomical efficacy was noted with IVD during the first month; however, reinjection at 4 months seemed more frequent with IVD than with IVB treatment.

show abstract

“…Similar data were found in the study by Cohen et al [25] with a mean intravitreal ranibizumab number of 3.5 (range 1–12) over a mean follow-up of 39.3 months. Pece et al [38] reported 2.3 intravitreal injections in the ranibizumab subgroup during 20-month follow-up; similarly, Iacono et al [16] reported a mean of 2.5 intravitreal ranibizumab injections over 18 months. A 6-year analysis by Ruiz-Moreno et al [22] revealed a mean of 3.3 injections, and in the longest study of ranibizumab monotherapy for mCNV, Hefner and Gerding [31] performed a mean of 3.5 injections (range 1–12) during a mean follow-up of 85 months.…”

Section: Discussionmentioning

confidence: 99%

Nine-Year Outcome of Ranibizumab Monotherapy for Choroidal Neovascularization Secondary to Pathologic Myopia

et al. 2017

Self Cite

View full text Add to dashboard Cite

Purpose: The aim of this study was to evaluate the 9-year outcome of ranibizumab monotherapy for myopic choroidal neovascularization (mCNV). Methods: This was a retrospective, nonrandomized, multicentric study to evaluate the long-term outcomes of mCNV treated with ranibizumab monotherapy for at least 9 years according to a strict pro re nata regimen. Results: Seventeen eyes of 17 patients (12 women, mean age 57.9 ± 7.7 years) were included. The mean follow-up period was 112.4 ± 3.9 months (range 108–120). The mean difference in best-corrected visual acuity (BCVA) from baseline to the last follow-up was +1.2 ± 15.6 ETDRS letters (p = 0.004, between initial vs. 12 and 24 months). The mean total number of intravitreal injections for each patient was 1.24 ± 1.70 per year (range 2–25). No systemic adverse reactions related to the drug treatment were detected during the 9-year follow-up period. Conclusions: Long-term ranibizumab monotherapy treatment induces unchanged or better BCVA compared to baseline after a 9-year treatment in almost all eyes.

show abstract

Intravitreal Ranibizumab Versus Bevacizumab for Treatment of Myopic Choroidal Neovascularization

Abstract: Intravitreal ranibizumab and IVB are effective in the treatment of subfoveal myopic choroidal neovascularization. Intravitreal ranibizumab achieved greater efficacy than IVB in terms of the mean number of injections administered.

Cited by 73 publications

References 31 publications

Anti-VEGF Therapy in Myopic Choroidal Neovascularization: Long-Term Results

Anti-VEGF Therapy in Myopic Choroidal Neovascularization: Long-Term Results

Prospective Pilot Study: Efficacy of Intravitreal Dexamethasone and Bevacizumab Injections in the Treatment of Macular Oedema Associated with Branch Retinal Vein Occlusion

Nine-Year Outcome of Ranibizumab Monotherapy for Choroidal Neovascularization Secondary to Pathologic Myopia

Contact Info

Product

Resources

About